Uric acid and inflammation in kidney disease
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Asymptomatic hyperuricemia is frequently observed in patients with kidney disease. Although a substantial number of epidemiologic studies have suggested that an elevated uric acid level plays a causative role in the development and progression of kidney disease, whether hyperuricemia is simply a result of decreased renal excretion of uric acid or is a contributor to kidney disease remains a matter of debate. Over the last two decades, multiple experimental studies have expanded the knowledge of the biological effects of uric acid beyond its role in gout. In particular, uric acid induces immune system activation and alters the characteristics of resident kidney cells, such as tubular epithelial cells, endothelial cells, and vascular smooth muscle cells, toward a proinflammatory and profibrotic state. These findings have led to an increased awareness of uric acid as a potential and modifiable risk factor in kidney disease. Here, we discuss the effects of uric acid on the immune system and subsequently review the effects of uric acid on the kidneys mainly in the context of inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 2×
“Upon its activation by specific danger stimuli, NLRP3 begins to oligomerize and recruit apoptosis-associated speck-like protein containing a CARD (ASC) and procaspase-1 (85).”
BackgroundGout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · cited 8×
“Given that kidney fibrosis is an inevitable consequence of sustained inflammation, fibrosis markers (transforming growth factor- , collagen, and -smooth muscle actin) are also improved by the use of XO inhibitors in murine models of DKD (61, 62, 70).”
BackgroundInfluentialReactive Oxygen Species in Metabolic and Inflammatory Signaling
Forrester, S. J., Kikuchi, D. S., Hernandes, M. S., Xu, Q., & Griendling, K. K. (2018) · Circulation Research · doi:10.1161/circresaha.117.311401 · Cited by 2,081
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832 · cited 8×
“Given that kidney fibrosis is an inevitable consequence of sustained inflammation, fibrosis markers (transforming growth factor- , collagen, and -smooth muscle actin) are also improved by the use of XO inhibitors in murine models of DKD (61, 62, 70).”
BackgroundInfluentialMolecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036
Inflammation and Progression of CKD: The CRIC Study
Amdur, R. L., Feldman, H. I., Gupta, J., Yang, W., Kanetsky, P., Shlipak, M., Rahman, M., Lash, J. P., Townsend, R. R., Ojo, A., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13121215 · Cited by 452
Niewczas, M. A., Pavkov, M. E., Skupien, J., Smiles, A., Md Dom, Z. I., Wilson, J. M., Park, J., Nair, V., Schlafly, A., Saulnier, P.-J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0415-5 · Cited by 432
Uric acid promotes an acute inflammatory response to sterile cell death in mice
Kono, H., Chen, C.-J., Ontiveros, F., & Rock, K. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40124 · Cited by 337 · cited 1×
“(68) clearly demonstrated these features of soluble uric acid acting as a DAMP in a mouse study using necrotic lung homogenates.”
Background
Cited by
Hyperuricemia and its related diseases: mechanisms and advances in therapy
Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01916-y · Cited by 631
Wang, J., Chen, Y., Zhong, H., Chen, F., Regenstein, J., Hu, X., Cai, L., & Feng, F. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1874287 · Cited by 317
Association of metabolic syndrome and chronic kidney disease
Scurt, F. G., Ganz, M. J., Herzog, C., Bose, K., Mertens, P. R., & Chatzikyrkou, C. (2024) · Obesity Reviews · doi:10.1111/obr.13649 · Cited by 155
“…of the individual pathomechanisms is beyond the scope of this review, so we would like to refer to the work of Jung et al. and Lee et al. 99,102 Despite the sound experimental data, in the clinical setting, pharmacologic interventions to reduce uric acid did not led to the anticipated…”
Background
Metadata
- Authors
- Jung, S. W., Kim, S.-M., Kim, Y. G., Lee, S.-H., & Moon, J.-Y.
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2020-06-01
- Volume
- 318
- Issue
- 6
- Pages
- F1327-F1340
- ISSN
- 1522-1466 (ISSN-L)
- 1931-857X
- OpenAlex
- W3013426744
- Cited by
- 190
- References
- 13
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Uric acid and inflammation in kidney disease. https://app.cochat.ai/papers/10.1152/ajprenal.00272.2019
- The paper
- Jung, S. W., Kim, S.-M., Kim, Y. G., Lee, S.-H., & Moon, J.-Y. (2020). Uric acid and inflammation in kidney disease. American Journal of Physiology-Renal Physiology. https://doi.org/10.1152/ajprenal.00272.2019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.